STAT Plus: Another patient charity settles charges it helped drug makers pay Medicare kickbacks
After a contentious, two-year battle with federal authorities, a patient charity called Patient Services agreed…
Category: Pharmalot
STAT Plus: Pharmalittle: Drug makers spent $120 million lobbying Congress in 2019; more investors are bullish in Biogen’s Alzheimer drug
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Many patient groups have deep ties to pharma but fail to disclose backing
Amid ongoing debate over the role the pharmaceutical industry plays in shaping health policy, a…
STAT Plus: Pharmalittle: Most Americans worry about drug prices, not Medicare for All; FDA remains divided over a drug
Top of the morning to you, and a fine one it is. Our short person…
STAT Plus: Civica Rx teams with Blue Cross Blue Shield to widen its alternative market for generics
In its latest bid to rework the marketplace for generic drugs, the Civica Rx nonprofit…
STAT Plus: European Court adviser deals Glaxo a setback in ‘pay-to-delay’ case
In a setback to GlaxoSmithKline (GSK), a legal adviser to the European Court of Justice…
STAT Plus: European court upholds controversial EMA transparency rules for clinical trial data
After months of anticipation, the European Court of Justice has sided with the European Medicines…
STAT Plus: Pharmalittle: Connecticut lawmakers look to cap insulin prices; Glaxo halts Excedrin production
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT Plus: As prescribing for ADHD stimulants rose, so did industry payments to doctors
At the same time that more doctors were prescribing stimulants, a new analysis finds that…
.jpg)
STAT Plus: Pharma is making some effort to fight superbugs, but progress is ‘patchy’
Amid rising concern over a lack of antibiotics, a new analysis finds most drug makers…
STAT Plus: Pharmalittle: Indian drug makers receive most FDA warning letters; most clinical trial results go unreported
Hello, everyone, and nice to see you again. We have finally returned from an extended…
STAT Plus: Pharmalittle: FTC member favors Medicare negotiation on drug prices; BioMarin weighs pricing world’s most expensive drug
Good morning. Elizabeth Cooney here again, channeling Ed Silverman as another week draws to a…
STAT Plus: Lilly exec says ‘there are no villains’ in the high-priced insulin market
Several months ago, Eli Lilly (LLY) launched LisPro, an authorized generic version of its Humalog…
STAT Plus: Pharmalittle: Roche plans aggressive SMA drug pricing; where are those clinical trial results?
Good morning. Elizabeth Cooney here in Boston while Ed Silverman hobnobs with industry types at…
STAT Plus: Pharmalittle: AstraZeneca fish oil pill flops; boom in biopharma dealmaking predicted for 2020
Good morning. Elizabeth Cooney sitting in for Ed Silverman, who is covering the J.P. Morgan…
High cost of multiple sclerosis medicines is forcing many patients to take ‘drastic actions’
The high cost of multiple sclerosis treatments has forced 40% of patients to take “drastic…
STAT Plus: Supreme Court will review an Arkansas law governing pharmacy benefit managers
In a move with the potential to affect health care costs, the U.S. Supreme Court…
STAT Plus: Pharmalittle: Combining antibiotics may cause resistance; Lilly moves into dermatitis market with $1.1 billion deal
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: Bristol-Myers and Sanofi accuse Hawaii of violating their free speech rights
In an unusual move, two of the world’s biggest drug makers — Bristol-Myers Squibb (BMY)…
STAT Plus: Pharmalittle: More companies recall heartburn tablets; Merck’s Keytruda wins another cancer approval
Top of the morning to you, and a fine one, it is, thanks to clear…
STAT Plus: Pharmalittle: More companies recall heartburn tablets; Merck’s Keytruda wins another cancer approval
Top of the morning to you, and a fine one, it is, thanks to clear…
STAT Plus: Pharmalittle: Execs vow to place patients ahead of profits; conservatives like Republican drug pricing bill
Good morning, everyone, and welcome to the middle of the week. Congratulations on making it…
STAT Plus: Pharmalittle: Few vets were treated with antidepressant Trump touted; Pelosi lashes out at price hikes
Good morning, everyone, and welcome to another working week. We hope the weekend respite was…
STAT Plus: Generic makers will appeal ruling that allows California to proceed with law banning pay-to-delay deals
A federal judge dealt the pharmaceutical industry a setback by declining to block a new…
STAT Plus: Pharmalittle: Lab urges FDA to recall all forms of Zantac; end-of-year FDA approval rush has unintended consequence
And so, another working week will soon draw to a close. A little quicker than…
STAT Plus: It’s ‘business as usual’ as many drug makers boost prices for the new year
A new year often means higher prices for prescription medicines and 2020 is no exception….
STAT Plus: Pharmalittle: FDA failed to police opioid prescribing program; Novo launches plan to mitigate insulin cost
Good morning, everyone, and welcome to a new year. We hope the extended respite —…
STAT Plus: Most Americans misunderstand approvals and FDA’s role in overseeing drug ads
The Food and Drug Administration may be a high-profile government agency, but a new survey…
STAT Plus: Prosecutors seek a 15-year jail sentence for former Insys CEO for his role in the opioid crisis
For his role in fomenting the opioid crisis, federal officials want to sentence Insys Therapeutics…
STAT Plus: As families in Europe clamor for its pricey gene therapy, Novartis creates a lottery
Seeking to provide its pricey gene therapy to patients in countries where the drug is…
STAT Plus: Pharmalittle: Trump proceeds with plan to allow importation; most Americans misunderstand FDA approvals
Hello, everyone, and how are you today? We are doing just splendidly, thank you, despite…
STAT Plus: Feds says a CVS long-term-care pharmacy improperly refilled prescriptions, jeopardizing patients
Omnicare, the nation’s largest long-term-care pharmacy, was accused by federal authorities of fraudulently billing government…
STAT Plus: Lawmakers say a Lilly program to offer half-price insulin is a bust
Several months ago, Eli Lilly (LLY) launched a new version of its Humalog insulin at…
STAT Plus: Amid fears of superbugs, sales of antibiotics used in food-producing livestock rose last year
In a surprise showing, the sale of medically important antibiotics given to food-producing livestock rose…
STAT Plus: Pharmalittle: FDA does about-face on rare disease drug; patent office pulls lawyer from Gilead case
And so, another working week will soon draw to a close. Not a moment too…
STAT Plus: U.S. Patent Office removes lawyer from high-profile case involving a Gilead HIV medicine
The U.S. Patent and Trademark Office has removed a senior legal adviser from a high-profile…
STAT Plus: GAO finds ongoing problems with FDA inspections of foreign drug facilities
Amid rising concern over the quality of the pharmaceutical supply chain, a government report finds…
STAT Plus: Lawmakers ask HHS for greater oversight of patient assistance programs
Amid ongoing concern about the use of patient assistance programs by the pharmaceutical industry, two…
STAT Plus: More hospital drug spending is going toward cancer immunotherapies
Amid intense scrutiny over prescription drug costs, a new analysis finds some hospitals are spending…
STAT Plus: Bribing doctors in India is allegedly a widespread practice
Seeking to juice profits, some Indian drug makers bribe doctors with credit cards, free trips,…
STAT Plus: What side effects? Problems with medicines may be vastly underreported to the FDA
It’s no secret that the many side effects caused by medicines do not get reported…
STAT Plus: A second generic drug maker admits to price fixing as part of a far-reaching probe into generics
A small drug maker called Rising Pharmaceuticals agreed to pay more than $3 million to…
STAT Plus: As Trump looks overseas for drug pricing ideas, one expert says France has some useful approaches
As the U.S. grapples with rising costs for prescription medicines, the Trump administration has floated…
STAT Plus: Pharmalittle: China to bulk-buy to lower drug costs; Senate bill to tackle drug prices going nowhere fast
Good morning, everyone, an welcome to another working week. We hope the weekend respite, which…
STAT Plus: Biogen will offer discounts to a health plan if patients say its multiple sclerosis drugs don’t work
In a twist on value-based contracting, a drug maker has agreed to offer a larger…
STAT Plus: Pharmalittle: Feds probe drug makers for flooding communities with opioids; States proceeding with importation
And so, another working week will soon come to an end, but earlier than usual,…
STAT Plus: EMA adopts EU Ombudsman recommendations to avoid bias concerns over drug approvals
Seeking to end another flap about transparency, the European Medicines Agency has agreed to recommendations…
STAT Plus: Pharmalittle: Generic makers talk to feds about ending price-fixing probe; how the Arnolds fueled the pricing debate in D.C.
Hello, everyone, and how are you today? We are doing just fine, thank you, now…
STAT Plus: Pharma execs tell researchers that multiple sclerosis drug pricing is based on competition, not R&D costs
Despite claims that prices for new medicines are generally shaped by R&D costs, initial pricing…
STAT Plus: Merck is probed by Spain’s antitrust regulator for allegedly delaying competition for a contraceptive
The antitrust regulator in Spain has accused Merck (MRK) of working with other companies to…